Recent News

• 09.16.2025 - Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
• 08.12.2025 - Financial results for the Second Quarter 2025 – conference call
• 08.12.2025 - Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
• 07.24.2025 - Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
• 07.21.2025 - Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
• 07.15.2025 - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.12.2025 - Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference

Recent Filings

• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.12.2025 - 8-K Current report
• 06.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 06.27.2025 - 8-K Current report
• 06.25.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.02.2025 - EX-99.1 EX-99.1
• 06.02.2025 - 8-K Current report
• 05.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]